Iridex reports Q3 revenue of $12.5 million, up 8% year-over-year

Reuters
2025/11/12
Iridex reports Q3 revenue of $12.5 million, up 8% year-over-year

Iridex Corporation reported third quarter 2025 revenue of $12.5 million, an 8.0% increase from $11.6 million in the same period of 2024. Revenue from the Cyclo G6 product family reached $3.5 million, up 13.0% year-over-year from $3.1 million. The company sold 14,900 Cyclo G6 probes compared to 13,600 a year earlier, and 30 Cyclo G6 Glaucoma Laser Systems versus 26 in the prior year quarter. Other revenue increased by $0.2 million to $2.2 million, mainly due to higher service revenue and sales of legacy products, partially offset by decreased royalties following patent expirations. As of September 27, 2025, cash and cash equivalents were $5.6 million, down $1.2 million for the quarter. Iridex expects to achieve positive adjusted EBITDA for the full year 2025 and anticipates cash flow breakeven in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572772-en) on November 11, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10